Your browser doesn't support javascript.

Biblioteca Virtual em Saúde

Brasil

Home > Pesquisa > ()
Imprimir Exportar

Formato de exportação:

Exportar

Email
Adicionar mais destinatários
| |

Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocations.

Visco, Carlo; Wang, Jinfen; Tisi, Maria Chiara; Deng, Lijuan; D'Amore, Emanuele S G; Tzankov, Alexandar; Montes-Moreno, Santiago; Dybkær, Karen; Bhagat, Govind; Hsi, Eric D; van Krieken, J Han; Ponzoni, Maurilio; Ferreri, Andrés J M; Møller, Michael B; Piris, Miguel A; Medeiros, L Jeffrey; Xu-Monette, Zijun Y; Young, Ken H.
Br J Cancer; 117(11): 1685-1688, 2017 Nov 21.
Artigo em Inglês | MEDLINE | ID: mdl-28949959

BACKGROUND:

The clinical presentation of patients with hepatitis C virus (HCV)-positive diffuse large B-cell lymphoma (DLBCL) is different from their HCV-negative counterparts, but the underlying molecular and pathological characteristics are largely under investigated. The virus has a role in lymphomagenesis, as witnessed by the curative potential of antiviral therapy in HCV-related low-grade B-cell lymphomas.

METHODS:

We performed a case-control study including 44 HCV-positive cases of de novo DLBCL, comparing them with 132 HCV-negative patients as controls (ratio 3 to 1). Cases and controls were matched for age, lactate dehydrogenase level and international prognostic index at presentation. Patients were studied by gene expression profiling for cell-of-origin determination and to perform differential expression analysis between groups, fluorescence in-situ hybridisation and immunohistochemistry for MYC, BCL2 and BCL6, TP53 mutations, and diagnostic specimens reviewed to exclude transformation from low-grade lymphoma.

RESULTS:

Compared to the HCV-negative controls, patients with HCV-positive de novo DLBCL had differential expression of genes that regulate innate immune response and modulate apoptotic pathways, have higher proliferative index, and lack BCL2 translocations.

CONCLUSIONS:

HCV-positive DLBCL have distinct molecular and pathological features compared to the HCV-negative counterparts.
Selo DaSilva